Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Crossref DOI link: https://doi.org/10.1007/s00393-016-0071-9
Published Online: 2016-04-14
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gissel, C.
Götz, G.
Repp, H.
License valid from 2016-04-14